Recent Advances in the Treatment of Pancreatic Cancer
Pembrolizumab has received tissue‑agnostic FDA approval for MSI‑high or deficient mismatch repair (dMMR) solid tumors, including pancreatic cancer.
Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer‑related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approach. This review will cover the most recent advances in the comprehensive treatment of pancreatic cancer and place them within a historical context when necessary. Treatment of all disease stages will be discussed, but the focus is on systemic therapy as novel drugs and new treatment combinations enter the clinic. This will include more aggressive chemotherapy in earlier disease stages, approved uses for immunotherapy, and targetable mutations. In addition, negative trials of importance and controversial topics will be noted.
Pancreatic cancer remains one of the most lethal malignancies worldwide, with limited therapeutic options. Advances in systemic and targeted therapies—particularly the approval of immunotherapy for MSI‑high tumors—offer new hope for improving survival and quality of life for patients.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Pancreatic cancer
- Modified FOLFIRINOX improves survival compared to gemcitabine in resected pancreatic cancer
- Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
- EUROPAC Researching Hereditary Pancreatic Diseases
- Excluded Studies - Screening for Pancreatic Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force - NCBI Bookshelf